Cencora, Inc.
Healthcare Distribution and Specialty PharmacyFounded 1985- Updated June 2026
Reviewed by Swet Parvadiya
Last reviewed: June 2026
CorpDigest
Cencora, Inc.
Company History
Founded 1985 in Conshohocken, Pennsylvania
Last reviewed: 2026-06-08 · By Swet Parvadiya
The origin of Cencora, Inc. is not a single founding moment but a complex evolution of corporate consolidation, operational innovation, and the brutal economics of the global pharmaceutical supply chain. The story begins in 1985 when Chemsource was founded in Pennsylvania, initially focusing on the distribution of generic pharmaceuticals and animal health products. The strategic shift occurred in the mid-2000s when the company successfully integrated the two distribution networks, implemented a unified IT system, and began to focus on the distribution of high-value specialty drugs and oncology therapies.
Steven H. Collis is an American business executive who served as the CEO of AmerisourceBergen (now Cencora) from 2001 until his retirement in early 2024. He played a pivotal role in the company's survival during the early 2000s integration crisis, navigating the massive debt load and operational inefficiencies of the Bergen Brunswig merger to transform the company into the second-largest pharmaceutical distributor in the world. Collis's background in operations and supply chain management gave him a unique perspective on the pharmaceutical industry, driving his focus on operational excellence, specialty pharmacy integration, and global logistics expansion. During his tenure, he oversaw the acquisition of over 50 companies, including World Courier, Healthcare Solutions, and Alto Pharmacy, which generated tens of billions of dollars in cumulative revenue and transformed the company from a traditional wholesale distributor into a diversified healthcare services platform. Collis was also known for his aggressive capital allocation strategy, which prioritized share repurchases and dividend growth while simultaneously managing the massive financial burden of the opioid litigation settlement. Despite the controversy surrounding the opioid crisis, Collis is widely credited with transforming Cencora from a struggling, low-margin distributor into a global healthcare services powerhouse, although his legacy is permanently intertwined with the regulatory and reputational challenges of the pharmaceutical supply chain.
The corporate lineage of Cencora began with the founding of Chemsource in Pennsylvania, initially focusing on the distribution of generic pharmaceuticals and animal health products.
Steven H. Collis orchestrated a series of aggressive acquisitions that transformed Chemsource into Amerisource Health, establishing a foothold in the national pharmaceutical distribution market.
Amerisource Health merged with Bergen Brunswig to form AmerisourceBergen, creating the second-largest pharmaceutical distributor in the United States and triggering a massive operational integration challenge.
CEO Steven H. Collis executed a brutal operational overhaul, slashing costs, unifying IT systems, and pivoting the company toward specialty distribution, saving the company from bankruptcy.
AmerisourceBergen acquired World Courier, establishing a dominant position in the global clinical logistics market and laying the foundation for the future Global Commercialization and Services segment.
The company launched Alto Pharmacy, a national specialty pharmacy network designed to capture the highest-margin segments of the drug supply chain and improve patient adherence.
Cencora, along with McKesson and Cardinal Health, agreed to a combined $21 billion national opioid settlement, with Cencora's share totaling approximately $6.4 billion to be paid through 2038.
AmerisourceBergen officially changed its name to Cencora, attempting to distance the corporate identity from the legacy wholesale distribution era and the stigma of the opioid litigation.
Cencora reported $278.0 billion in global revenue for FY2024, with operating income reaching $3.5 billion and free cash flow at $4.5 billion, demonstrating strong performance post-rebrand.
Cencora acquired Alto Pharmacy to establish a national specialty pharmacy network designed to capture the highest-margin segments of the drug supply chain and improve patient adherence.
Cencora acquired World Courier to establish a dominant position in the global clinical logistics market and lay the foundation for the future Global Commercialization and Services segment.
Cencora acquired Healthcare Solutions to secure a leading group purchasing organization (GPO) platform and expand its presence in the alternate care site market.
Cencora (formerly AmerisourceBergen) was created through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, combining two pharmaceutical distributors to create what was then the largest US pharmaceutical wholesaler with $34 billion combined revenue. The merger followed Bergen Brunswig's 1999 acquisition of PharMerica that had stressed its finances, with AmeriSource's stronger operational performance leading the consolidation. Strategic rationale included pharmaceutical distribution scale economies, geographic complementarity (AmeriSource's eastern US strength combined with Bergen Brunswig's western US presence), and operational efficiencies through consolidated distribution networks. The combined entity grew through subsequent decade to become one of three dominant pharmaceutical distributors (with McKesson and Cardinal Health) controlling 90%+ of US pharmaceutical wholesale distribution.
AmerisourceBergen rebranded to Cencora in August 2023 to reflect transformation from US-focused pharmaceutical wholesaler to global healthcare solutions company with operations across multiple countries and expanded service capabilities beyond pharmaceutical distribution. The 'Cencora' name combines 'centric' (customer-centric) with 'core' (essential to healthcare) representing strategic positioning as central healthcare infrastructure provider. The rebrand followed 2021 acquisition of Walgreens Boots Alliance Pharmaceutical Wholesale Division (Alliance Healthcare) for $6.3 billion that significantly expanded international operations particularly in UK and continental Europe. The new identity supports global brand recognition across diverse markets where 'AmerisourceBergen' lacked meaning, plus signals strategic identity beyond pure pharmaceutical distribution toward broader healthcare services. The brand transition cost approximately $50-100 million across various jurisdictions but reflects strategic intent to grow beyond historical US wholesale identity.
Cencora became the world's largest pharmaceutical distributor by revenue ($278 billion 2024) through combination of organic growth, strategic acquisitions, and operational excellence in pharmaceutical wholesale logistics. Major growth drivers include long-term Walgreens contract (one of largest pharmaceutical distribution contracts globally), specialty pharmaceutical growth (oncology drugs, biologics), and Alliance Healthcare acquisition providing European scale. The competitive positioning emerged from disciplined acquisition strategy, customer relationship development, and operational efficiency supporting thin-margin distribution at enormous scale. Revenue growth from $34 billion (2001 merger) to $278 billion (2024) represents extraordinary expansion through pharmaceutical industry growth, market share gains, and strategic acquisitions. Cencora's distribution operations handle hundreds of billions of dollars in pharmaceuticals annually, with sophisticated logistics, temperature control, and regulatory compliance capabilities supporting complex healthcare supply chain.
Cencora (then AmerisourceBergen) agreed to pay $6.4 billion as part of $26 billion 'Big Three' distributor settlement (2021) addressing allegations that pharmaceutical distributors failed to monitor and report suspicious opioid orders fueling the opioid epidemic causing 600,000+ overdose deaths since 2000. The settlement structure provided 18-year payment schedule reducing annual financial impact to manageable levels (~$350 million annually), plus operational changes including enhanced controlled substance monitoring systems. Additional state and local government opioid settlements have added various amounts totaling several billion dollars in cumulative opioid liability. The opioid crisis significantly affected Cencora's strategic flexibility for the decade requiring settlement payments, reduced capital available for acquisitions and growth investment, and damaged company reputation requiring continued compliance and remediation focus. However, financial impact has been manageable within company's overall operating cash flow, allowing continued strategic execution alongside settlement obligations.
The first full year under the Cencora name brought both an expansive M&A move and an unwelcome cyber incident that tested the rebranded distributor's risk profile. On February 21, 2024 Cencora disclosed in an SEC 8-K that an unauthorised actor had exfiltrated data from its IT environment on February 12, 2024 including personally identifiable information belonging to patients of certain pharmaceutical-manufacturer clients that used Cencora's patient-support and specialty-services platforms. The breach forced individual notifications across multiple states and triggered class-action lawsuits, with Cencora declining to identify the affected manufacturers but confirming the company had taken its compromised systems offline, notified law enforcement and engaged Mandiant. Even with the breach, Cencora delivered roughly $262 billion in fiscal 2024 revenue, keeping it the largest US pharmaceutical distributor ahead of McKesson and Cardinal Health. The Pharmalex acquisition, closed October 2, 2023 for €1.28 billion (about $1.4 billion) from AUCTUS Capital Partners, added regulatory affairs, pharmacovigilance and market-access consulting to deepen the post-AmerisourceBergen services portfolio that began with World Courier (2012) and MWI Veterinary Supply (2015 for $2.5 billion). On October 1, 2024 Bob Mauch succeeded Steven Collis as CEO, with Collis remaining executive chair, completing a planned transition first announced in November 2023 and giving Mauch authority to integrate Pharmalex, restore IT resilience and manage the long-running Alliance Healthcare partnership with Walgreens Boots Alliance.